Supplementary Data from Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
Jane C. Figueiredo(University of Southern California), Akil Merchant(University of Southern California), Jennifer E. Van Eyk(Cedars-Sinai Smidt Heart Institute), Edwin C. Frias(Abbott (Germany)), Carissa A. Huynh(Cedars-Sinai Medical Center), Nathalie Huỳnh Châu Nguyễn(Cedars-Sinai Medical Center), Joslyn Foley(Cedars-Sinai Medical Center), Susan Cheng(Cedars-Sinai Medical Center), Omid Hamid(Cedars-Sinai Medical Center), Jonathan Braun(Cedars-Sinai Medical Center), Laurel J. Finster(Cedars-Sinai Medical Center), Dermot McGovern(Salford Royal NHS Foundation Trust), So Yung Choi(Cedars-Sinai Medical Center), Reva Basho(Larry Ellison Foundation), Emebet Mengesha(Cedars-Sinai Medical Center), James L. Stewart(Abbott (United States)), John C. Prostko(Abbott Fund), Noah Merin(Cedars-Sinai Medical Center), Wendy Cozen(University of Southern California), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Greg Botwin(Immunosciences Lab (United States)), Gil Melmed, Warren G. Tourtellotte(Cedars-Sinai Medical Center), Sandy Joung(Cedars-Sinai Smidt Heart Institute), Kimia Sobhani(Cedars-Sinai Medical Center), Justin Darrah(Cedars-Sinai Medical Center), Jun Gong(Cedars-Sinai Medical Center), Joseph E. Ebinger(Cedars-Sinai Medical Center), Robert Vescio(Royal Adelaide Hospital), Ronald Paquette, Alain C. Mita(Cedars-Sinai Medical Center), Tucker Lemos(Cedars-Sinai Medical Center), Inderjit Mehmi
Cited by 0
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k